933782-03-7

Basic information

• Product Name: (2-bromo-4-methylthiazol-5-yl)methanol
• Synonyms: (2-bromo-4-methylthiazol-5-yl)methanol
• CAS NO: 933782-03-7
• Molecular Weight: 208.079
• Mol File: 933782-03-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (2-bromo-4-methylthiazol-5-yl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (2-bromo-4-methylthiazol-5-yl)methanol(933782-03-7)
• EPA Substance Registry System: (2-bromo-4-methylthiazol-5-yl)methanol(933782-03-7)

Safety Data

• Hazardous Substances Data: 933782-03-7(Hazardous Substances Data)

Usage

Description

(2-bromo-4-methylthiazol-5-yl)methanol is a chemical compound with the molecular formula C7H7BrNOS. It is a thiazole derivative that contains a bromine atom. (2-bromo-4-methylthiazol-5-yl)methanol has potential applications in medicinal chemistry and drug discovery due to its structural features and potential pharmacological properties. It may also be used as a building block in organic synthesis to develop new molecules with specific biological activities. Its unique structure and reactivity make it a valuable tool for researchers in various fields of science. However, it is important to handle this compound with care due to its potentially harmful effects and toxicity.

Uses

Used in Medicinal Chemistry and Drug Discovery:
(2-bromo-4-methylthiazol-5-yl)methanol is used as a chemical compound in medicinal chemistry and drug discovery for its potential pharmacological properties and structural features.
Used in Organic Synthesis:
(2-bromo-4-methylthiazol-5-yl)methanol is used as a building block in organic synthesis to develop new molecules with specific biological activities.
Used in Research:
(2-bromo-4-methylthiazol-5-yl)methanol is used as a valuable tool for researchers in various fields of science due to its unique structure and reactivity.

Upstream product

• 7210-76-6 ethyl-2-amino-4-methylthiazole-5-carboxylate 
• 22900-83-0 ethyl 2-bromo-4-methyl-1,3-thiazole-5-carboxylate 

Downstream Products

• 1011532-51-6 (S)-ethyl 3-(4-((2-bromo-4-methylthiazol-5-yl)methoxy)phenyl)-3-(isoxazol-3-yl)propanoate 
• 317318-74-4 2-{2-methyl-4-[({4-methyl-2-[4-chlorophenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid 

Relevant articles and documents

Parallel Chemistry Approach to Identify Novel Nuclear Receptor Ligands Based on the GW0742 Scaffold

We describe the parallel synthesis of novel analogs of GW0742, a peroxisome proliferator-activated receptor δ (PPARδ) agonist. For that purpose, modified reaction conditions were applied, such as a solid-phase palladium-catalyzed Suzuki coupling. In addition, tetrazole-based compounds were generated as a bioisostere for carboxylic acid-containing ligand GW0742. The new compounds were investigated for their ability to activate PPARδ mediated transcription and their cross-reactivity with the vitamin D receptor (VDR), another member of the nuclear receptor superfamily. We identified many potent PPARδ agonists that were less toxic than GW0742, where ～65 of the compounds synthesized exhibited partial PPARδ activity (23-98%) with EC50 values ranging from 0.007-18.2 μM. Some ligands, such as compound 32, were more potent inhibitors of VDR-mediated transcription with significantly reduced PPARδ activity than GW0742, however, none of the ligands were completely selective for VDR inhibition over PPARδ activation of transcription.

HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES

The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.

Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals

The inventive compounds of the present invention are comprised of phenyl and pyridinyl-1,2,4-oxadiazolone derivatives and their physiologically acceptable salts and functional derivatives that are shown to provide peroxisome proliferator activator recepto